Chromatin topology defines estradiol-primed Progesterone Receptor and PAX2 binding in endometrial cancer cells

GRECA, ALEJANDRO LA; BELLORA, NICOLÁS; DILY, FRANCOIS LE; JARA, RODRIGO; NACHT, ANA SILVINA; OLIETE, JAVIER QUILEZ; VILLANUEVA, JOSÉ LUIS; VIDAL, ENRIQUE; MERINO, GABRIELA; FRESNO, CRISTÓBAL; RIESCHLE, INTI TARIFA; VALLEJO, GRISELDA; VICENT, GUILLERMO; FERNÁNDEZ, ELMER; BEATO, MIGUEL; SARAGÜETA, PATRICIA

eLife

eLife Sciences Publications Ltd

Lugar: Cambridge; Año: 2022 vol. 11

Estrogen (E2) and Progesterone (Pg), via their specific receptors (ERalpha and PR), are major determinants in the development and progression of endometrial carcinomas, However, their precise mechanism of action and the role of other transcription factors involved are not entirely clear. Using Ishikawa endometrial cancer cells, we report that E2 treatment exposes a set of progestin-dependent PR binding sites which include both E2 and progestin target genes. ChIP-seq results from hormone-treated cells revealed a non-random distribution of PAX2 binding in the vicinity of these estrogen-promoted PR sites. Altered expression of hormone regulated genes in PAX2 knockdown cells suggests a role for PAX2 in fine-tuning ERalpha and PR interplay in transcriptional regulation. Analysis of long-range interactions by Hi-C coupled with ATAC-seq data showed that these regions, that we call "progestin control regions" (PgCRs), exhibited an open chromatin state even before hormone exposure and were non-randomly associated with regulated genes. Nearly 20% of genes potentially influenced by PgCRs were found to be altered during progression of endometrial cancer. Our findings suggest that endometrial response to progestins in differentiated endometrial tumor cells results in part from binding of PR together with PAX2 to accessible chromatin regions. What maintains these regions open remains to be studied.